A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV
Latest Information Update: 05 Oct 2023
At a glance
- Drugs JNJ 64400141 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Janssen Vaccines and Prevention B.V
- 27 Sep 2022 Status changed from recruiting to completed.
- 01 Sep 2022 The trial has been completed in Germany, according to European Clinical Trials Database record
- 18 Jan 2022 Planned End Date changed from 14 Jun 2022 to 4 Aug 2022.